Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine.

Literature DB >> 22298822

MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine.

Massimo Breccia, Adriano Salaroli, Giuseppina Loglisci, Paola Finsinger, Alessandra Serrao, Giuliana Alimena.

Abstract

Entities: Chemical Disease Species

Mesh：

Year: 2012 PMID： 22298822 PMCID： PMC3269466 DOI： 10.3324/haematol.2011.059808

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

4 in total

1. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.

Authors: Matteo G Della Porta; Luca Malcovati; Corinna Strupp; Ilaria Ambaglio; Andrea Kuendgen; Esther Zipperer; Erica Travaglino; Rosangela Invernizzi; Cristiana Pascutto; Mario Lazzarino; Ulrich Germing; Mario Cazzola
Journal: Haematologica Date: 2010-12-06 Impact factor: 9.941

2. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

Authors: Bruce D Cheson; Peter L Greenberg; John M Bennett; Bob Lowenberg; Pierre W Wijermans; Stephen D Nimer; Antonio Pinto; Miloslav Beran; Theo M de Witte; Richard M Stone; Moshe Mittelman; Guillermo F Sanz; Steven D Gore; Charles A Schiffer; Hagop Kantarjian
Journal: Blood Date: 2006-04-11 Impact factor: 22.113

3. Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes.

Authors: Massimo Breccia; Vincenzo Federico; Giuseppina Loglisci; Adriano Salaroli; Alessandra Serrao; Giuliana Alimena
Journal: Haematologica Date: 2011-10 Impact factor: 9.941

4. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

Authors: Raphael Itzykson; Sylvain Thépot; Bruno Quesnel; Francois Dreyfus; Odile Beyne-Rauzy; Pascal Turlure; Norbert Vey; Christian Recher; Caroline Dartigeas; Laurence Legros; Jacques Delaunay; Célia Salanoubat; Sorin Visanica; Aspasia Stamatoullas; Francoise Isnard; Anne Marfaing-Koka; Stephane de Botton; Youcef Chelghoum; Anne-Laure Taksin; Isabelle Plantier; Shanti Ame; Simone Boehrer; Claude Gardin; C L Beach; Lionel Adès; Pierre Fenaux
Journal: Blood Date: 2010-10-12 Impact factor: 22.113

4 in total

3 in total

MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine.

1. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.

2. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

3. Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes.

4. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

1. Integrating patient-centered factors in the risk assessment of MDS.

Review 2. Improving Prognostic Modeling in Myelodysplastic Syndromes.

Review 3. Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.